Phreesia, Inc. (NYSE: PHR), a leading healthcare technology company, saw its stock soar 5.13% in pre-market trading on Tuesday. This surge can be attributed to the company's impressive third-quarter fiscal 2025 results and an optimistic outlook for the upcoming fiscal year.
In its earnings report, Phreesia announced a 17% year-over-year increase in revenue, reaching $106.8 million. The company also reported positive adjusted EBITDA of $9.8 million, a significant improvement of $16.4 million compared to the previous year. Additionally, Phreesia achieved positive operating cash flow of $5.8 million and free cash flow of $1.6 million, further strengthening its financial position.
Encouraged by the strong performance, Phreesia raised its fiscal 2025 adjusted EBITDA guidance to a range of $34 million to $36 million, up from the previous range of $26 million to $31 million. Furthermore, the company provided an optimistic outlook for fiscal 2026, expecting revenue to grow by 13% to 15% and adjusted EBITDA to increase by a staggering 129% to 144%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。